With regard to SGLT-2 inhibitors, a substantially higher risk of genital infections was analyzed with their use than in those using metformin in insulin-receiving T2DM patients (adjusted OR 1.76; 95% CI 1.07–2.90, p = 0.03). Here, SLC5A2 is linked to type 2 diabetes mellitus.